The semaglutide products licensed in the UK — and what each one is actually for

The biggest misconception: "semaglutide" and "Wegovy" are the same thing

Most people who search for semaglutide products are really asking about weight loss. And semaglutide can help with weight loss, but only in its specific licensed forms, at the right dose. The misconception is that any semaglutide product will do. It won't.

Ozempic is semaglutide. So is Rybelsus. Both are made by Novo Nordisk, both contain the same molecule, and both are licensed in the UK exclusively for type 2 diabetes. Prescribing either for weight management when someone doesn't have diabetes is off-label use, and the NHS semaglutide guidance is clear that different products carry different authorisations. A clinical service operating within the law will not simply hand over whichever brand someone has heard of.

Wegovy is the version of semaglutide licensed for weight management. It runs at a higher maintenance dose than Ozempic (2.4mg weekly for the injection, and up to 25mg daily for the tablet) and it has gone through a separate regulatory approval process specifically for obesity treatment. That approval matters, because it means the evidence base and the safety profile have been assessed by the MHRA for that use, at those doses. The detail of what separates each product is covered on our full semaglutide guide.

The three semaglutide products and what they actually do

Breaking this down clearly:

Wegovy injection is a once-weekly subcutaneous injection, titrated from 0.25mg up to 2.4mg (and now up to 7.2mg with the MHRA-approved higher-dose pen, approved 14 April 2026). It is licensed for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition. A dedicated page on Wegovy in the UK covers the full licence picture, including the NICE recommendation under NICE technology appraisal TA875.

Wegovy tablet received MHRA approval on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. The tablet starts at 1.5mg daily and escalates through 4mg and 9mg to a 25mg maintenance dose, with at least a month at each stage. No refrigeration is needed, which changes the practical picture considerably for travel or anyone without easy fridge access. Clinical trial data from the OASIS 4 trial showed an average weight loss of around 13.6% over 64 weeks (around 17% among participants who stayed fully adherent throughout). Full background on Wegovy product information is worth reading before your consultation.

Ozempic and Rybelsus are not weight-loss products. Ozempic is injected weekly; Rybelsus is a daily tablet at 3mg, 7mg or 14mg, doses that are entirely separate from the Wegovy tablet schedule. If you have type 2 diabetes and your GP has prescribed one of these, that is a different clinical conversation from weight management.

Why the licensing distinction isn't just paperwork

It can feel like an administrative technicality. It isn't. Licensing means the dose, the titration schedule, the evidence for benefit and the monitoring for risk have all been assessed for a specific use. Using a diabetes-dose semaglutide product at a dose it was never trialled at for weight loss means stepping outside the evidence base entirely.

It also has practical consequences. Supply. Monitoring. Clinical review at each stage. The kind of supply chain that backs a licensed product in the UK is regulated; the grey market is not. The MHRA has warned publicly about counterfeit and illegally supplied medicines, and semaglutide products have featured heavily in those seizures.

For anyone thinking about cost (and it's a fair question) our guide to Wegovy pricing in the UK sets out what the honest market looks like and why a low headline number sometimes signals a risk rather than a deal. The short version: for a prescription medicine, the cheapest option answers the wrong question.

How a GLP-1 works, and why semaglutide is one of several

Semaglutide works by activating GLP-1 receptors, which are involved in appetite regulation, gastric emptying and blood-sugar control. Slowing the rate at which the stomach empties helps people feel fuller for longer, and the appetite signal changes mean most people eat less without a constant battle of willpower. That's the biology, stripped back.

It's worth knowing that semaglutide is a GLP-1 receptor agonist only, a single-pathway medicine. Tirzepatide (Mounjaro) activates both GLP-1 and GIP receptors, which is why head-to-head trial results have generally favoured tirzepatide for average weight loss. Whether semaglutide or tirzepatide suits a particular person depends on their health history, other medicines they take and clinical judgement, not a comparison table alone. Our page on how semaglutide relates to naturally occurring gut hormones explains the mechanism in more detail.

One practical note: if you're planning to start treatment, timing your consultation for a Monday or Tuesday means same-day clinical review and dispatch can land the pen or tablet with you before the week is out. Orders placed around bank holidays follow the next available working day, so it's worth bearing in mind if you're planning ahead. When you're ready, our prescribers are the right people to talk to, speak to our clinical team or check what suits you via a free consultation.